Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab

The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to major challenges in the therapeutic management of patients living with multiple sclerosis (PLwMS), particularly regarding the use of disease-modifying therapies. D...

Descripción completa

Detalles Bibliográficos
Autores principales: Pedotti, Rosetta, Muros-Le Rouzic, Erwan, Raposo, Catarina, Schippling, Sven, Jessop, Nikki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349416/
https://www.ncbi.nlm.nih.gov/pubmed/34411984
http://dx.doi.org/10.1016/j.msard.2021.103203
_version_ 1783735560371699712
author Pedotti, Rosetta
Muros-Le Rouzic, Erwan
Raposo, Catarina
Schippling, Sven
Jessop, Nikki
author_facet Pedotti, Rosetta
Muros-Le Rouzic, Erwan
Raposo, Catarina
Schippling, Sven
Jessop, Nikki
author_sort Pedotti, Rosetta
collection PubMed
description The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to major challenges in the therapeutic management of patients living with multiple sclerosis (PLwMS), particularly regarding the use of disease-modifying therapies. Despite an extraordinary scientific effort to study SARS-CoV-2 in PLwMS, the heterogeneity of COVID-19 manifestations, immunological mechanisms induced by the natural infection or the vaccines, and the extent of protection through the vaccines, major knowledge gaps remain. Here, we describe the scientific evidence generation plan developed by Roche/Genentech to better understand the impact of the COVID-19 pandemic in PLwMS treated with the B-cell depleting monoclonal antibody ocrelizumab.
format Online
Article
Text
id pubmed-8349416
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-83494162021-08-09 Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab Pedotti, Rosetta Muros-Le Rouzic, Erwan Raposo, Catarina Schippling, Sven Jessop, Nikki Mult Scler Relat Disord Article The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to major challenges in the therapeutic management of patients living with multiple sclerosis (PLwMS), particularly regarding the use of disease-modifying therapies. Despite an extraordinary scientific effort to study SARS-CoV-2 in PLwMS, the heterogeneity of COVID-19 manifestations, immunological mechanisms induced by the natural infection or the vaccines, and the extent of protection through the vaccines, major knowledge gaps remain. Here, we describe the scientific evidence generation plan developed by Roche/Genentech to better understand the impact of the COVID-19 pandemic in PLwMS treated with the B-cell depleting monoclonal antibody ocrelizumab. Elsevier B.V. 2021-10 2021-08-08 /pmc/articles/PMC8349416/ /pubmed/34411984 http://dx.doi.org/10.1016/j.msard.2021.103203 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Pedotti, Rosetta
Muros-Le Rouzic, Erwan
Raposo, Catarina
Schippling, Sven
Jessop, Nikki
Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab
title Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab
title_full Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab
title_fullStr Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab
title_full_unstemmed Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab
title_short Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab
title_sort understanding the impacts of covid-19 pandemic in people with multiple sclerosis treated with ocrelizumab
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349416/
https://www.ncbi.nlm.nih.gov/pubmed/34411984
http://dx.doi.org/10.1016/j.msard.2021.103203
work_keys_str_mv AT pedottirosetta understandingtheimpactsofcovid19pandemicinpeoplewithmultiplesclerosistreatedwithocrelizumab
AT muroslerouzicerwan understandingtheimpactsofcovid19pandemicinpeoplewithmultiplesclerosistreatedwithocrelizumab
AT raposocatarina understandingtheimpactsofcovid19pandemicinpeoplewithmultiplesclerosistreatedwithocrelizumab
AT schipplingsven understandingtheimpactsofcovid19pandemicinpeoplewithmultiplesclerosistreatedwithocrelizumab
AT jessopnikki understandingtheimpactsofcovid19pandemicinpeoplewithmultiplesclerosistreatedwithocrelizumab

Ejemplares similares